The Role of Dendritic Cells in Hepatitis C Infection

The role of the dendritic cells, the most potent antigen presenting cells, in the establishment of chronic hepatitis C is not established. The study aims to define whether the dendritic cells are affected by the hepatitis C virus and whether that bears an impact on the antiviral immune response they generate. The hypothesis is explored by investigating a group of patients prior to and after the initiation of standard treatment for hepatitis C with pegylated Interferon and Ribavirin.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Hepatitis C Infection

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University College Hospital

London, NW1 2BU, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

anti-HCV positive
HCV RNA positive

Exclusion criteria

contraindications for antiviral treatment
concurrent chronic viral infections

Treatment and study plan

Viraferon-peg and Rebetol

Drug

Primary outcomes

Basic science research (immunology of hepatitis C)in hepatitis c patients receiving established, standard antiviral treatment (pegylated Interferon+Ribavirin)

Sponsors and collaborators

Lead sponsor

University College, London

Other

Collaborators

Schering-Plough

Registry information

Important dates

Study start: 2002
Primary completion: 2004
Study completion: 2004
First posted: Jul 28, 2008
Registry last updated: Jul 28, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed